Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784461 | 0.88 | PSMB5 (0.53) | PSMB5HSD11B1SKP2BACE1GPR3 | |
| SCHEMBL1784380 | 0.83 | MAPT (0.46) | PSMB5BACE1NPC1MAPK1RAB9A | |
| SCHEMBL11325207 | 0.83 | PSMB5 (0.61) | PSMB5HSD11B1SKP2BACE1GPR3 | |
| SCHEMBL10654561 | 0.80 | PSMB5 (0.62) | PSMB5HSD11B1SKP2BACE1GPR3 | |
| SCHEMBL23432416 | 0.80 | SKP2 (0.59) | PSMB5HSD11B1SKP2BACE1GPR3 | |
| SCHEMBL4591101 | 0.79 | BACE1 (0.66) | PSMB5HSD11B1BACE1NPC1MAPK1 | |
| SCHEMBL27992110 | 0.77 | GPR3 (0.50) | PSMB5HSD11B1GPR3RARBMAPK1 | |
| SCHEMBL11512580 | 0.75 | HSD11B1 (0.62) | PSMB5HSD11B1CA1CA2RARB | |
| SCHEMBL21693629 | 0.75 | PSMB5 (0.54) | PSMB5HSD11B1GPR3RARBMAPK1 | |
| SCHEMBL6546416 | 0.75 | PSMB5 (0.57) | PSMB5HSD11B1SKP2GPR3RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323975-B1 | MULTI-RING ANTIOXIDANTS WITH ANTIWEAR PROPERTIES | SI GROUP INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-9796939-B2 | Multi-ring antioxidants with antiwear properties | SI GROUP, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20140038871-A1 | MULTI-RING ANTIOXIDANTS WITH ANTIWEAR PROPERTIES | ALBEMARLE CORPORATION (US) | 2014-02-06 | — | — | US | disclosed |
| US-8580718-B2 | Multi-ring antioxidants with antiwear properties | ALBERMARLE CORPORATION (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110124540-A1 | MULTI-RING ANTIOXIDANTS WITH ANTIWEAR PROPERTIES | ALBEMARLE CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2323975-A2 | MULTI-RING ANTIOXIDANTS WITH ANTIWEAR PROPERTIES | Albemarle Corporation (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010011523-A2 | MULTI-RING ANTIOXIDANTS WITH ANTIWEAR PROPERTIES | ALBEMARLE CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124540-A1 | MULTI-RING ANTIOXIDANTS WITH ANTIWEAR PROPERTIES | GSR, CBR1, SOD1 | PSMB5 2779/4885HSD11B1 300/4885SKP2 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.